Arbutus Biopharma (ABUS) just unveiled an announcement.
At Arbutus Biopharma Corporation’s 2024 Annual General and Special Meeting, shareholders backed significant changes to its 2016 Omnibus Share and Incentive Plan, notably a substantial increase in the number of shares allocated for issuance and incentive stock options. Additionally, they elected director nominees, endorsed executive compensation, and confirmed Ernst & Young LLP as the independent auditor for the upcoming fiscal year, highlighting a strong alignment between the company’s management and its shareholders’ interests.
Learn more about ABUS stock on TipRanks’ Stock Analysis page.
